Drug intelligence / Profile preview

XQ-1H

Development stage: Unknown
Lead developer: Nanjing Carephar Pharmaceutical
Modality: Small Molecules
Administration: Intravenous

Overview

XQ-1H is a small molecule derivative of ginkgolide B, specifically 10-O-(N,N-dimethylaminoethyl)-ginkgolide B methanesulfonate, developed by Nanjing Carephar Pharmaceutical for the treatment of ischemic stroke. It acts as a platelet-activating factor (PAF) antagonist with enhanced water solubility compared to its parent compound. Preclinical studies indicate that XQ-1H provides neuroprotection and anti-inflammatory effects by regulating microglia polarization and the Wnt/β-catenin signaling pathway. It is currently in Phase 1 clinical development in both injection and tablet formulations.

Other names: 10-O-(N,N-dimethylaminoethyl)-ginkgolide B methanesulfonate

Targets

PTAFR (Platelet-activating factor receptor)

Beyond the preview

Go deeper on XQ-1H.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XQ-1H.

Explore the full profile